Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Jerini

1984 FOUNDED
M&A STATUS
101-200 EMPLOYEES
M&A LATEST DEAL TYPE
$551M LATEST DEAL AMOUNT
Description

Developer and marketer of peptide-based drugs. The company offers Firazyr (Icatibant) for the treatment of acute attacks of hereditary angioedema. Its developing product pipeline includes JSM 6427, a a5ß1 Integrin antagonist for the treatment of cancer, age-related mascular degeneration-blindness in the elderly, and angiogenesis, inflammation, and fibrosis; and JSM-7717 and JPE-1375, which are C5a receptor antagonists for the treatment of inflammatory and ophthalmological diseases.

Website
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • Invalidenstrasse 130
  • 10115 Berlin
  • Germany
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Jerini’s full profile, request a free trial.

Jerini Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 03-Jul-2008 $551M 00000 00000 Completed Generating Revenue
3. IPO 01-Nov-2005 000.00 00000 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 09-Jun-2004 $37.7M $43.1M Completed Generating Revenue
1. Early Stage VC (Series A) $5.48M $5.48M Completed
To view this company’s complete deal history including valuation and funding, request access »

Jerini Former Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
3i Group PE/Buyout Minority 000 0000 000000 0
Edelman Financial Services Asset Manager Minority 000 0000 000000 0
HealthCap Venture Capital Minority 000 0000 000000 0
IBB Beteiligungsgesellschaft Venture Capital Minority 000 0000 000000 0
KfW Group Investment Bank Minority 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »